IN THE CLAIMS

1. (Original) A novel pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid of the formula



2. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



3. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



4. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



5. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



6. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



7. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



8. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



9. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



10. (Original) A pyrrolo[2, 1-c] [1,4] benzodiazepine hybrid as claimed in claim 1 having the formula



11. (Original) A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula V



n = 3 - 5 V

which comprises reacting a 4- (1H- benzo[d] imidazol-2-yl) phenol of the formula I



I

with – [4-(n- bromoalkyloxy)-5- methoxyy-2- nitrobenzo-yl] pyrrolidine- 2-carboxaldehyde diethyl thio acetal of formula II



II

in the presence of K_2 CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {4-(1H- benoz [d] imidazolo- 2 yl) phenoxy] alkyl - oxy- 5 methoxy- 2-nitrobenzoyl} pyrrolidine-2- carboxaldehyde diethyl thioacetal III



III

where "n" is 3 to 5, reducing said compound of formula III with $SnCl_2$ $2H_2O$ in the presence of organic solvent up to a reflux temperature, isolating the (2S) -N- {n- 4- (1H- benzo [d] imidazolo- 2yl)phenoxy]alkyl]-oxy-5-methoxy-2-aminobenzoyly} pyrrolidine- 2-carboxaldehyde diethyl thioacetal of the formula IV



IV

where n is 3 to 5 by known methods, reacting the said amino compound of formula IV with conventional deprotecting agents in to produce pyrrolo [2,1-c]1,4] benzodiazepine hybrids of formula V, wherein "n" is as defined above.

12. A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula IX



n = 3 - 5 IX

which comprises reacting a 4- [6-4.- methylhexahydro- 1- pyrazinyl)- 1H - benzo [irnidazol- 2- yl] phenol VI



VI

with N-[4-(n-bromoalkyloxy)-5- methoxy-2-nitrobenzo-yl]pyrrolidine- 2-carboxaldehyde diethyl thio acetal of formula II



II

in the presence of $K_2 CO_3$ in organic solvent for a period of 12 to 24 hrs, isolating (2S)-N- {n-(4- [6-4- methylhexahydro-l- pyraxinzyl)- 1H- benzo [d] imidazol- 2-yl] phenoxy] alkyl-oxy-5- methoxy-2- nitrobenzoy pyrrolidine-2- carboxaldehyde diethyl thioacetal VII



VII

where "n" is 3 to 5, reducing said compound of formula VII with SnCl2O in the presence of organic solvent up to a reflex temperature, isolating (2S)-N- {n- (4- [6-(4-methylhexahydro-l-pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenoxy] alkyl)-oxy-5- methoxy -2- aminobenzoy) pyrrolidine-2- carboxaldehyde diethyl thioacetal VIII



VII

and reacting the said amino compound of formula VIII with conventional deprotecting agents in to produce pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula IX wherein "n".

13. (Original) A process for the preparation of pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula XIII



n = 3 - 5 XIII

which comprises reacting a 4- [6-(4- ehtylhexahydro- I-pyrazinyl)- 1H- benzo [d] imidazol-2- yl] phenol X



X +

with – [4-(n- bromoalkyloxy)-5- methoxyy-2,- nitrobenzo-yl] pyrrolidine- 2- carboxaldehyde diethyl thio acetal of formula II



II

in the presence of K_2 CO_3 in organic solvent for a period of 12 to 24 hrs, isolating (2S)- – {n-(4- [6-4- ehtyhexahydro-l- pyrazinyl)- H- benzo [d] imidazol-2- yl] phenoxy] alkyll] - oxy- 5- methoxy- 2- nitrobenzoyl) pyrrolidine- 2- carboxaldehyde diethyl thioacetal XI



XI

where "n" is 3 to 5, reducing said compound of formula XI with $SnCl_2 . 2H_2O$ in the presence of organic solvent up to a reflux temperature, isolating (2S)-N- {n-(4-[6-(4-ethylhexahydro-1-pyrazinyl)-1H - benzo[d] imidazol-2- yl] phenoxy] alkyl)- oxy-5- methoxy-2- aminobenzoyl} pyrrolidine- 2- carboxaldehyde diethyl thioacetal XII where n is 3 to 5



XI

and reacting the said amino compound of formula XII with conventional deprotecting agents to produce pyrrolo [2,1-c] 1, 4] benzodiazepine hybrids of formula XIII wherein "n" is as defined above.

14. (Currently amended) Use of a pyrrolo [2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in ~~anyone of claims~~ claim 1 ~~to 10~~ for the preparation of medicament useful for treating tumours.

15. (Currently amended) A pharmaceutical composition for use as antitumour agents comprising of an effective amount of a pyrrolo [2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in ~~anyone of claims~~ claim 1 ~~to 10~~.

16. (Currently amended) A method of treating a mammal which comprises administering an affective amount of a pyrrolo [2,1-c] 1, 4] benzodiazepine hybrid compound as claimed in ~~anyone of claims~~ claim 1 ~~to 10~~.

17. (Original) A method of treating a mammal, which comprises administering an affective amount of a pharmaceutical composition as claimed in claim 15.